CTP Director Authors FDA Voices Blog on Decline in Youth Tobacco Product Use

Dec.05.2024
CTP Director Authors FDA Voices Blog on Decline in Youth Tobacco Product Use
Dr. Brian King, Director of U.S. FDA Center for Tobacco Products, announced that youth smoking rates have reached a historic low, while e-cigarette use has dropped to its lowest level in nearly a decade. Despite these significant strides, FDA stated that it will continue to take measures to protect youth from the harms of tobacco products.

Dr. Brian King, Director of U.S. Food and Drug Administration (FDA) Center for Tobacco Products (CTP), announced that, according to the 2024 National Youth Tobacco Survey, youth tobacco product use has dropped to its lowest level in 25 years. Cigarette smoking among youth has reached a historic low, while e-cigarette use among youth has dropped to the lowest level in a decade. This achievement is the result of efforts at multiple levels, including federal and local policy implementation, public education, and strict enforcement. Despite the significant progress, the FDA stated that it will continue to take action to protect youth from the harms of tobacco products.

 

Below is the original article written by Dr. Brian King:

 

 

Youth Tobacco Product Use Continues to Decline as FDA Actions Build Momentum

 

 

By: Dr. Brian King, Director of FDA's Center for Tobacco Products

 

As Director of the U.S. Food and Drug Administration's Center for Tobacco Products (CTP), I often reflect on conversations with the public, including the people behind tobacco product use statistics. This type of reflection started in the early days of my career when I answered calls for a tobacco quit line. On a daily basis, I spoke with people who had a desire to quit smoking. Each had a different reason for wanting to quit: living to meet their grandchildren, walking their child down the wedding aisle, or taking a dream vacation with their spouse. While their reasons varied, they had heartbreaking similarities – a deep desire to be there for their families and to celebrate life's precious moments with the ones they love.

 

Dr. Brian King
Dr. Brian King

 

We know most adults who use tobacco products first started during adolescence. That's why keeping tobacco products out of the hands of youth is central to our mission. That said, the recently released 2024 National Youth Tobacco Survey findings are a monumental win for public health: youth tobacco product use has dropped to its lowest level ever reported since the survey began a quarter century ago. Cigarette smoking among youth has reached a historic low. Moreover, reductions in e-cigarette use have fueled recent progress, with use of these products among youth dropping to the lowest level in a decade.

 

This success is the result of actions taken at the national, state, local, territorial and tribal levels. National actions include those by the FDA, which is taking a robust, comprehensive approach to tobacco regulation – and it's no coincidence that current youth tobacco product use in the U.S. decreased from 4.67 million in 2009, when CTP was established, to 2.25 million in 2024.

 

Importantly, the FDA's work in this area is not over. CTP's policy agenda guides and provides transparency on our plans, including current and long-term priorities. For example, the FDA recently advanced one of its priorities through a final rule outlining increased age requirements for tobacco product sales. Most adults who smoke daily smoked their first cigarette by young adulthood, so enforcing the federal minimum age-of-sale of 21 for tobacco products is critical.

 

Another way the agency continues to protect youth is through our review of applications for new tobacco products. A major component of CTP's review includes considering the youth who might start using the product. In fact, we've taken action on more than 26 million applications, including denying the marketing of e-cigarettes in youth-appealing designs and flavors, including candy and fruit. 

 

At the same time, we have also authorized thirty-four e-cigarette products for sale, including those with tobacco and menthol flavors. These authorized products and devices have undergone rigorous scientific review and have been found by the FDA to meet the public health standard required by law – which weighs the risks of the products against the benefits to the population as a whole. In the case of flavored e-cigarettes, this includes demonstrating they have a benefit for adults who smoke cigarettes relative to that of tobacco flavored e-cigarettes – in terms of complete switching or significant reduction – that is sufficient to outweigh the risks of the product, including to youth.

 

We also protect youth from the risks of tobacco products through enforcement actions. The FDA uses multiple tools, including warning letters, civil money penalties, injunctions, and seizures to ensure those across the supply chain obey laws that prevent youth tobacco product use. We also work with other federal agencies on e-cigarette enforcement, including through a newly formed interagency task force.

 

Education plays a crucial role in preventing youth tobacco initiation and use. For example, our awarding-winning campaign "The Real Cost" has been estimated to prevent hundreds of thousands of youth from starting to use tobacco products each year. These efforts are a public health "best buy" – for every $1 we spend on the campaign, an estimated $180 in savings occurs for society through averted tobacco-related health costs. The campaign continues to reach – and positively impact – teens. We also provide outreach to parents and teachers, offering free resources such as our Vaping Prevention and Education Resource Center.
 
All the above activities are part of the FDA's ongoing efforts to make tobacco-related disease and death part of our nation's past, ensuring a healthier future for our youth. While this progress is promising, there's more work to do and we remain committed to protecting our nation's youth from the harms of tobacco products.

 

Special Report|CrossBar's High-Puff Vapes Draw Attention on Pennsylvania's 163-Product Directory as Link Between Earlier 1.3mL PMTA Filings and New 13mL Products Remains Unclear
Special Report|CrossBar's High-Puff Vapes Draw Attention on Pennsylvania's 163-Product Directory as Link Between Earlier 1.3mL PMTA Filings and New 13mL Products Remains Unclear
Pennsylvania began enforcing its electronic nicotine delivery system directory restrictions on October 19, 2026. Among 163 product listings recorded before enforcement, four CrossBar 20K disposables stood out with 13mL capacity, advertised puff counts of up to 20,000 and a flattened design distinct from conventional pod systems and compact disposables. Historical records identify earlier 1.3mL CrossBar products associated with Romo LLC, while newer 13mL products appeared in several state directories beginning in 2025 under entities including Blue Nine LLC. PMTA compliance expert Mr. K identified amendments and application ownership transfers as possible regulatory mechanisms, although neither has been confirmed in this case. Separately, Reynolds' $7.5 million acquisition of 16 PACHA products and related assets illustrates the commercial value of products linked to historic PMTA submissions.
Special Report
Oct.22
Sweden Threatens EU Tobacco Tax Deal as Nicotine Pouch Duty Dispute Looms Over November 9 Meeting
Sweden Threatens EU Tobacco Tax Deal as Nicotine Pouch Duty Dispute Looms Over November 9 Meeting
Sweden is expected to oppose a European Union proposal to raise minimum tobacco excise duties, Law360 reported on October 26, 2026, citing an EU official. A provisional Council agenda dated October 23 confirms that the tobacco taxation package is scheduled for discussion at the November 9 finance ministers' meeting, where member states will seek a general approach. The proposed reforms would raise minimum taxes on conventional tobacco products and establish EU-wide excise rules for vaping liquids, heated tobacco and nicotine pouches. Sweden supports harmonising tobacco taxation rules but objects to requiring nicotine pouches to bear the same minimum tax burden as certain smoking tobacco products. As EU indirect tax legislation requires unanimous Council approval, Swedish opposition could block the proposal in its current form.
Regulations
Oct.29
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Vaping brand PIXL has introduced the PIXL 5K reusable prefilled pod device in the UK, featuring a 2ml prefilled pod and a 4ml refill container with a combined e-liquid capacity of 6ml. The device uses 20mg/ml nicotine salt e-liquid and is advertised to deliver up to approximately 5,000 puffs. Available through UK retailers by August 2026, the PIXL 5K sits alongside the existing 12ml PIXL 8000. The UK's Vaping Products Duty took effect on October 1 at £0.22 per millilitre, producing theoretical duty amounts of £1.32 and £2.64 for the two products' respective full refill sets.
product
Oct.10
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
UK Directors Banned After 352,688 Vapes Imported From China Were Misdeclared as Medical Nebulizers in £15 Million Tax Case
The UK Insolvency Service said YSK Enterprises imported large quantities of vapes from China in 2023, with a shipment addressed to the company declared as medical nebulizers before Border Force found 352,688 vaping products. HMRC calculated nearly £15 million ($20.3 million) in unpaid VAT and customs duty, alongside about £437,000 in corporation tax. Two directors were disqualified for nine years. The case predates the UK's Vaping Products Duty, which will introduce vape-specific excise and duty-stamp requirements from October 2026.
Regulations
Sep.11